Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
19.00 +0.11 (+0.58%) 11:33 ET [NASDAQ]
18.97 x 15 19.02 x 151
Realtime by (Cboe BZX)
18.97 x 15 19.02 x 151
Realtime 19.12 +0.23 (+1.22%) 09:30 ET
Quote Overview for Thu, Feb 27th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
18.74
Day High
19.52
Open 19.13
Previous Close 18.89 18.89
Volume 169,892 169,892
Avg Vol 815,747 815,747
Stochastic %K 4.96% 4.96%
Weighted Alpha -19.38 -19.38
5-Day Change -2.66 (-12.32%) -2.66 (-12.32%)
52-Week Range 14.56 - 33.33 14.56 - 33.33
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,718,687
  • Shares Outstanding, K 143,922
  • Annual Sales, $ 330,530 K
  • Annual Income, $ -145,220 K
  • EBIT $ -490 M
  • EBITDA $ -517 M
  • 60-Month Beta 1.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.10

Options Overview Details

View History
  • Implied Volatility 93.40% ( +9.00%)
  • Historical Volatility 64.63%
  • IV Percentile 96%
  • IV Rank 83.78%
  • IV High 102.52% on 12/20/24
  • IV Low 46.31% on 01/21/25
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 2,103
  • Open Int (30-Day) 2,101

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.83
  • Number of Estimates 13
  • High Estimate -0.41
  • Low Estimate -0.97
  • Prior Year -0.86
  • Growth Rate Est. (year over year) +3.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.67 +1.39%
on 02/26/25
Period Open: 23.19
24.34 -22.24%
on 02/05/25
-4.26 (-18.37%)
since 01/27/25
3-Month
18.52 +2.21%
on 01/14/25
Period Open: 25.16
26.18 -27.69%
on 12/09/24
-6.23 (-24.76%)
since 11/27/24
52-Week
14.56 +30.01%
on 04/25/24
Period Open: 23.35
33.33 -43.20%
on 11/11/24
-4.42 (-18.93%)
since 02/27/24

Most Recent Stories

More News
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

DNLI : 19.00 (+0.58%)
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicleâ„¢ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposiumâ„¢

DNLI : 19.00 (+0.58%)
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

DNLI : 19.00 (+0.58%)
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

DNLI : 19.00 (+0.58%)
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

DNLI : 19.00 (+0.58%)
Denali Therapeutics Initiates Phase 2a Clinical Study of LRRK2 Inhibitor BIIB122 for Parkinson’s Disease

Denali Therapeutics initiates a Phase 2a study of BIIB122 for LRRK2-associated Parkinson's disease, evaluating safety and biomarkers.Quiver AI SummaryDenali Therapeutics Inc. has announced the start of...

DNLI : 19.00 (+0.58%)
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

DNLI : 19.00 (+0.58%)
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

DNLI : 19.00 (+0.58%)
Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Bio-Techne has underperformed the healthcare sector over the past year, yet analysts remain strongly bullish about the stock’s prospects.

TECH : 62.58 (-2.45%)
XLV : 148.61 (+0.53%)
DNLI : 19.00 (+0.58%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 19.00 (+0.58%)
FHTX : 4.88 (-2.59%)
MRNA : 32.20 (-4.11%)
OMGA : 0.1426 (-10.82%)
SANA : 2.78 (+6.51%)
MCRB : 0.7468 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 20.47
2nd Resistance Point 20.06
1st Resistance Point 19.48
Last Price 19.00
1st Support Level 18.49
2nd Support Level 18.08
3rd Support Level 17.50

See More

52-Week High 33.33
Fibonacci 61.8% 26.16
Fibonacci 50% 23.95
Fibonacci 38.2% 21.73
Last Price 19.00
52-Week Low 14.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements